PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 September; 4(3): 18–23.
Published online 2003 May 14. doi:  10.1208/pt040331
PMCID: PMC2750624

Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system

Abstract

The effect of concentration of hydrophilic (hydroxypropyl methylcellulose [HPMC]) and hydrophobic polymers (hydrogenated castor oil [HCO], ethylcellulose) on the release rate of tramadol was studied. Hydrophilic matrix tablets were prepared by wet granulation technique, while hydrophobic (wax) matrix tablets were prepared by melt granulation technique and in vitro dissolution studies were performed using United States Pharmacopeia (USP) apparatus type II. Hydrophobic matrix tablets resulted in sustained in vitro drug release (>20 hours) as compared with hydrophilic matrix tablets (<14 hours). The presence of ethylcellulose in either of the matrix systems prolonged the release rate of the drug. Tablets prepared by combination of hydrophilic and hydrophobic polymers failed to prolong the drug release beyond 12 hours. The effect of ethylcellulose coating (Surelease) and the presence of lactose and HPMC in the coating composition on the drug release was also investigated. Hydrophobic matrix tablets prepared using HCO were found to be best suited for modulating the delivery of the highly water-soluble drug, tramadol hydrochloride.

Keywords: tramadol, hydrogenated vegetable oil, hydroxypropyl methylcellulose, ethylcellulose, melt granulation

Full Text

The Full Text of this article is available as a PDF (263K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Lehmann KA. Tramadol in acute pain. Drugs. 1997;53(suppl 2):25–33. [PubMed]
2. Scott LJ, Perry CM. Tramadol: a review of its use in perioperative pain. Drugs. 2000;60(1):139–176. doi: 10.2165/00003495-200060010-00008. [PubMed] [Cross Ref]
3. Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm. 1997;23:929–938. doi: 10.3109/03639049709148697. [Cross Ref]
4. Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Tech Prod Mfr. 1984;5:1–9.
5. Liu J, Zhang F, McGinity JW. Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion. Eur J Pharm Biopharm. 2001;52:181–190. doi: 10.1016/S0939-6411(01)00162-X. [PubMed] [Cross Ref]
6. Vickers MD, O Flaherty D, Szekely SM, Read M, Yushizumi J. Tramadol: pain relief by an opioid without depression of respiration. Anaesthesia. 1992;47:291–296. doi: 10.1111/j.1365-2044.1992.tb02166.x. [PubMed] [Cross Ref]
7. Houmes RJ, Votes MA, Verkaaik A, Erdmann W, Lachmann B. Efficacy and safety of tramadol for moderate and severe postoperative pain with special regard to respiratory depression. Anesth Analg. 1992;74:510–514. doi: 10.1213/00000539-199204000-00007. [PubMed] [Cross Ref]
8. Liao S, Hill JF, Nayk RK. Pharmacokinetics of tramadol following single and multiple oral doses in man. Pharm Res. 1992;9(suppl):308–308.
9. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37(July):17–40. doi: 10.2165/00003088-199937010-00002. [PubMed] [Cross Ref]
10. Hummel T, Roscher S, Pauli E, Frank M, Liefhold J, Fleischer W, Kobal G. Assessment of analgesia in man: tramadol controlled release formula vs tramadol standard formulation. Eur J Clin Pharmacol. 1996;51(1):31–38. doi: 10.1007/s002280050156. [PubMed] [Cross Ref]
11. Malonne H, Fontaine J, Moes A. In vitro/in vivo characterization of a tramadol HCl depot system composed of monoolein and water. Biol Pharm Bull. 2000;23(5):627–631. [PubMed]
12. Zhang ZY, Ping QN, Xiao B. Microencapsulation and characterization of tramadol-resin complexes. J Control Release. 2000;66(2–3):107–113. doi: 10.1016/S0168-3659(99)00273-4. [PubMed] [Cross Ref]
13. Hogan JE. Hydroxypropyl methylcellulose sustained release technology. Drug Dev Ind Pharm. 1989;15(27):975–999. doi: 10.3109/03639048909043660. [Cross Ref]
14. Kibbe AH. Handbook of Pharmaceutical Excipients. 3rd ed. London, UK: Pharmaceutical Press; 2000. pp. 94–95.
15. Yonezawa Y, Ishida S, Sunanda H. Release from or through a wax matrix system. I. Basic release properties of the wax matrix system. Chem Pharm Bull. 2001;49:1448–1451. doi: 10.1248/cpb.49.1448. [PubMed] [Cross Ref]
16. Obaidat Ayliman A., Rana M. Obaidat, Controlled release of tramadol hydrochloride from matrices prepared using glycerbehenate. Eur J Pharm Biopharm. 2001;52:231–235. doi: 10.1016/S0939-6411(01)00173-4. [PubMed] [Cross Ref]
17. Sanchez-Lafuente C, Teresa Faucci M, Fernandez-Arevalo M, Alvarez-Fuentes J, Rabasco AM, Mura P. Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. Int J Pharm. 2002;234(1–2):213–221. doi: 10.1016/S0378-5173(01)00962-0. [PubMed] [Cross Ref]
18. Sadeghi F, Ford JL, Rubinstein MH, Rajabi-Siahboomi AR. Study of drug release from pellets coated with Surelease containing hydroxypropyl methylcellulose. Drug Dev Ind Pharm. 2000;27(5):419–430. doi: 10.1081/DDC-100104317. [PubMed] [Cross Ref]
19. Tang L, Schwartz JB, Porter SC, Schanaare RL, Wigent RJ. Drug release from film-coated chlorpheniramine maleate nonpareil beads: effect of water-soluble polymer, coating level, and soluble core material. Pharm Dev Tech. 2000;5(3):383–390. doi: 10.1081/PDT-100100554. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists